Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04960397 |
|
Recruitment Status :
Recruiting
First Posted : July 13, 2021
Last Update Posted : October 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a Phase 1b, randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled study of 200 children, ages 6 months to 17 years. This clinical trial is designed to assess the safety, tolerability/reactogenicity, and immunogenicity of one and two doses of Sing2016 M2SR H3N2 influenza vaccine (manufactured by FluGen) administered intranasally in seven cohorts of children.
The first two groups to be vaccinated will be Cohorts 1 and 2. Cohort 1 consists of 45 children 9-17 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^9 TCID50, and 15 will receive one dose of placebo. Cohort 2 comprises 45 children 2-8 years old. Thirty of them will receive one dose of the vaccine at a dose of 10^8 TCID50 and 15 will receive one dose of placebo.
Cohort 3 consists of 25 children 2-8 years old. 15 of them will receive one dose of vaccine at 10^9 TCID50 and 10 will receive one dose of placebo. Once 25 participants in Cohort 3 have completed Day 8 of follow-up, similar to Cohorts 1 and 2, the SRC will review to ensure no halting rules are met and if no rules are met, and the SRC determines it is safe to proceed, simultaneous enrollment into Cohorts 4 and 5 can begin. If any halting rules are met or any concerns are raised by the SRC, an external SMC may meet to discuss the data for recommendations on either progression or clinical trial modification before progression to the next cohort.
Cohort 4 consists of 25 children 2-8 years old; 15 of them will receive two doses of vaccine at 10^9 TCID50 and 10 will receive two doses of placebo, with a 28-day interval between the first and second doses. Cohort 5 will enroll 8 influenza naïve children (defined as children without receipt of influenza vaccine and without previous documented influenza infection) who are 6-23 mo who will be randomly assigned to receive two doses of 10^7 TCID50 Sing2016 M2SR (n=6) or two doses of placebo (n=2) with a 28-day interval between the first and second dose. Once all 25 participants in Cohort 4 and all 8 of Cohort 5 have completed Day 36 of follow-up, the SRC will conduct a safety assessment to begin enrollment in Cohort 6.
Cohorts 6 and 7 will also enroll 6- to 23-month-olds who are influenza-naïve. Cohort 6 will consist of 26 children. A lead-in group of 8 children will be randomly assigned to receive either two doses of 10^8 TCID50 of the Sing2016 M2SR (n=6) or two doses of placebo (n=2). Once the first 8 children have completed Day 8 (8 days after first dose), the SRC will review the safety and determine if Cohort 7 may open to enrollment. Cohort 7 enrollment will not begin until Cohort 6 is fully enrolled. Similar to other cohorts, the additional 18 children in Cohort 6 may continue to enroll during the SRC review.
Cohort 7 will be the final cohort. Twenty-six children will be randomly allocated to receive two doses of either 10^9 TCID50 Sing2016 M2SR (n=18) or placebo (n=8). This cohort does not have a "lead-in" group since data from such a group are not needed to allow the enrollment in a subsequent cohort. However, the study-wide and individual halting rules still apply.
The primary study objective is to assess the safety and tolerability of one and two administrations of the Sing2016 M2SR H3N2 influenza vaccine at 10^7, 10^8, or 10^9 TCID50 delivered intranasally to healthy participants, 6 months to 17 years of age
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| H3N2 Influenza | Other: Placebo Biological: Sing2016 M2SR H3N2 | Phase 1 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Masking Description: | Participants, site investigators, and study personnel performing any study-related assessments following study product administration are blinded to product received. Laboratory personnel performing immunological assays will receive serum blinded to participant ID number, specimen visit number, and allocation group. |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 1b, Double-Blind, Randomized, Dose-Escalating, Age De-Escalating, Placebo-Controlled Study to Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine Delivered Intranasally In a Healthy Pediatric Population 6 Months Through 17 Years of Age. |
| Actual Study Start Date : | September 10, 2021 |
| Estimated Primary Completion Date : | November 1, 2023 |
| Estimated Study Completion Date : | November 1, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
A cohort of influenza non-naïve 45 healthy children, 9-17 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1. N=45.
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 2
A cohort of influenza non-naïve 45 healthy children, 2-8 years old, will receive a single dose of 10^8 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1 intranasally. N= 45
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 3
Once, there is sufficient evidence of safety and tolerability in Cohorts 1 and 2,and enrollment has completed of all 45 in each of these cohorts. Cohort 3 will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or placebo (N=10) at Day 1. N=25.
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 4
Once, there is sufficient evidence of safety and tolerability in Cohort 3 and enrollment has been completed for this cohort, and fifth cohorts (Cohorts 4 and 5) will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive two doses of the 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or two doses of placebo (N=10) at Day 1 and Day 29. N=25
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 5
Participants in Cohort 4, will enroll concurrently. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomized to receive two doses of 10^7 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=8.
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 6
Once, there is sufficient evidence of safety in Cohort 5, Cohort 6 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, where a lead-in group (N=20) will be randomly assigned to receive either two doses of 10^8 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=20. Once lead-in group completes Day 8, the SRC will review the safety and determine if Cohort 7 may begin enrollment. Additional group of children may continue to enroll during the SRC review, which will be assigned randomly to receive two doses of 10^8 TCID50 of intranasal Sing2016 M2SR (N=12) or two doses of placebo (N=6) at Day 1 and Day 29. N= 26
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
|
Experimental: Cohort 7
Once, there is sufficient evidence of safety in Cohort 6, Cohort 7 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomly assigned to receive two doses of 10^9 TCID50 dose of intranasal Sing2016 M2SR vaccine (N=18) or two doses of placebo (N=8) at Day 1 and Day 29. N=26
|
Other: Placebo
Physiological saline, i.e., 0.9% sodium chloride. Biological: Sing2016 M2SR H3N2 Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc. |
- Occurrence of Adverse Events of Special Interest (AESIs) [ Time Frame: Day 1 through Day 395 ]
- Occurrence of New-onset Chronic Medical Conditions (NOCMCs) [ Time Frame: Day 1 through Day 395 ]
- Occurrence of Serious Adverse Event (SAEs) [ Time Frame: Day 1 through Day 395 ]
- Occurrence of solicited reactogenicity Adverse Events (AEs) [ Time Frame: Through 7 days post vaccination ]Both local and systemic solicited reactogenicity adverse events (AEs) will be assessed.
- Occurrence of unsolicited non serious Adverse Events (AE) [ Time Frame: Through 28 days post vaccination ]
- Change from baseline in Geometric Mean Fold Rise (GMFR) in Hemagglutination inhibition (HAI) antibody titers [ Time Frame: Day 1 through Day 57 ]Hemagglutination inhibition (HAI) antibody titers against an H3N2 M2SR-like virus
- Change from baseline in Geometric Mean Fold Rise (GMFR) in neutralization titers [ Time Frame: Day 1 through Day 57 ]Neutralization titers against an H3N2 M2SR-like virus
- Change from baseline in Geometric mean titer (GMT) of secretory Immunoglobulin A (sIgA) [ Time Frame: Day 1 through Day 57 ]Secretory ImmunoglobulinA (sIgA) against an H3N2 M2SR-like virus
- Geometric mean fold rise (GMFR) of secretory Immunoglobulin A (sIgA) [ Time Frame: Day 1 through Day 57 ]Secretory ImmunoglobulinA (sIgA) against an H3N2 M2SR-like virus
- Geometric Mean Titers (GMTs) of serum Hemagglutination inhibition (HAI) antibody [ Time Frame: Up to Day 57 ]Hemagglutination inhibition (HAI) antibody against an H3N2 M2SR-like virus
- Geometric Mean Titers (GMTs) of serum neutralizing antibodies [ Time Frame: Up to Day 57 ]Serum neutralizing antibodies against an H3N2 M2SR-like virus
- Occurrence of greater than or equal to 2- and 4-fold mean rises in Hemagglutination inhibition (HAI) antibody titers [ Time Frame: Day 1 through Day 57 ]Hemagglutination inhibition (HAI) antibody titers against an H3N2 M2SR-like virus
- Occurrence of greater than or equal to 2- and 4-fold mean rises in neutralization titers [ Time Frame: Day 1 through Day 57 ]Neutralization titers against an H3N2 M2SR-like virus
- Occurrence of neutralization titer > / =1:40 [ Time Frame: Up to Day 57 ]Neutralization titer > / =1:40 against an H3N2 M2SR-like virus
- Occurrence of putative seroprotection [ Time Frame: Up to Day 57 ]Seroprotection defined as Hemagglutination inhibition (HAI) antibody titer > / = 1:40 against an H3N2 M2SR-like virus
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Months to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
1. Participant is a male or female child aged 6 months to 17 years inclusive at time of enrollment (each cohort has its own age upper and lower limits*)
-
Cohort 1: 9-17 years (on or after the ninth birthday and before the eighteenth birthday at the time of the first dose); Cohorts 2, 3, and 4: 2-8 years (on or after the second birthday and before the ninth birthday at the time of the first dose); Cohorts 5, 6, and 7: 6 months to 23 months (on or after the sixth month of life based on calendar day and before the second birthday at the time of the first dose) 2. For Cohorts 1 to 4, receipt of at least 2 doses of seasonal influenza vaccine in the past.
3. For Cohorts 5 to 7, receipt of no seasonal influenza vaccines in the past and no documented history of laboratory-confirmed influenza illness 4. Parent/guardian of the participating child provides written informed permission and participating child provides assent* prior to initiation of any study procedures
- As appropriate by age or development and approved by the Institutional Review Board (IRB) 5. Parent/guardian and participant, as appropriate, are able to understand and comply with planned study procedures and are available for all study visits 6. Participant is in good health as assessed by the principal investigator or other designated study investigator*
- Based on medical history and physical examination (physical examination may be done as part of routine medical care or specifically for eligibility screening) 7. Parent/guardian of the participating child agrees not to allow the participant to join another clinical trial that includes an investigational agent or device during the study period 8. A female participant of child-bearing potential* agrees to abstain from sexual intercourse or to correctly use an acceptable method of contraception**
-
A female of child-bearing potential is defined as a female who is post-menarchal and not sterilized via tubal ligation, bilateral oophorectomy, salpingectomy, hysterectomy, or successful Essure (R) placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure. This applies only to participants in Cohort 1.
**Acceptable methods of contraception must be used from 30 days prior to vaccination until 60 days after the last study vaccination (not Inactivated Influenza Vaccine (IIV4)) and include full abstinence from sexual intercourse with a male partner, monogamous relationship with vasectomized partner who has been vasectomized for 180 days or more or shown to be azoospermic prior to the participant receiving the study vaccination, barrier methods such as condoms or diaphragms/cervical cap, intrauterine devices, NuvaRing (R), and licensed hormonal methods such as implants, injectables, or oral contraceptives ("the pill").
9. A female participant of child-bearing potential must have a negative urine pregnancy test within 24 hours prior to each study product 10. A male who is sexually active with a female of childbearing potential must agree to use an acceptable method of contraception*
- From the time of the first dose of study vaccine until 60 days after receipt of the last dose study vaccine, only in cohort 1. The only acceptable method of contraception for males who are sexually active with females of childbearing potential is condoms.
Exclusion Criteria:
-
Has a body temperature of 38 degrees Celsius or 100.4 degrees Fahrenheit (oral or axillary) or greater or another acute illness* within the 72 hours prior to study vaccination
*Potential participants who are recovering from an acute illness and have residual minimal symptoms, which, in the opinion of the site principal investigator or appropriate sub-investigator, will not likely affect the evaluation of outcome measures are not ineligible. Temperature evaluation will not be performed as a study procedure on participants prior to administration of seasonal influenza vaccine
-
Has any medical or mental health disease or condition* that would render study participation unsafe, or would interfere with the evaluation of the responses
*In the opinion of the site principal investigator or appropriate sub-investigator
- Has a history of provider-diagnosed asthma requiring the use of medications at any age or has had a wheezing episode or use of medications to treat asthma in the 12 months prior to screening.
- Has immunosuppression as a result of an underlying illness or treatment, a recent history or current use of immunosuppressive or immunomodulating disease therapy
- Has a diagnosis of or history of malignant neoplastic disease
- Has taken oral, parenteral (intramuscular or intravenous), inhaled, or nasal corticosteroids of any dose within 30 days prior to study vaccination
- Has known HIV, hepatitis B, or hepatitis C infection
-
Has known hypersensitivity or allergy to any components of the study vaccine or material in the nasal delivery device*
*Vaccine components: sucrose, sodium chloride, phosphate, glutamate; delivery device material: polycarbonate, polypropylene, synthetic rubber
- Has a history of severe reactions following previous immunization with licensed or unlicensed influenza vaccines
- Has a history of an anatomic disorder of the nares or nasopharynx
- Has a history of chronic sinus infections
- Has a history of or currently smokes or vapes
- Has a history of Guillain-Barré syndrome
- Use of aspirin- or salicylate-containing products in the 30 days prior to or intends to use these products in the 30 days following administration of the investigational vaccine
- Has a history of documented influenza or receipt of influenza antiviral treatment in the 4 months prior to the first vaccination
- Receipt of any antiviral drug within the week prior to or following the investigational vaccine.
- Receipt of a licensed live vaccine within 30 days prior to the first study vaccination or plans to receive a licensed live vaccine within the 30 days after the last study vaccination.
- Receipt of licensed inactivated non-influenza vaccine within 14 days prior to the first study vaccination, or plans to receive licensed, inactivated vaccine within the 30 days after the last study vaccination. ** Participants will be asked to avoid receipt of any routine licensed vaccines or vaccines under emergency use authorization during the periods described.
- Receipt of an influenza vaccine within the 4 months prior to the first study vaccination or plans to receive an influenza vaccine following the last study vaccination. Seasonal IIV4 will be received by participants as part of this trial.
- Receipt of immunoglobulin or other blood products within the 6 months prior to the first study vaccination or plans to receive during the period of study participation.
-
Receipt of an experimental* agent or device within the 6 months prior to the first study vaccination or expects to receive an experimental agent or device during the study period.
*Products for treatment or prevention of coronavirus disease 2019 (COVID-19), when received under Emergency Use Authorization (EUA) or full FDA approval and not as part of a clinical trial, will not be deemed "experimental" for the purposes of this criterion and will not make an otherwise eligible prospective participant ineligible.
- Is a family member of study personnel or personnel directly involved in the conduct or monitoring of the study.
-
Receipt of an approved or experimental product for treatment or prevention of COVID-19 within the 10 days prior to study enrollment.
- Participants may enroll if greater than 10 days after receipt of the COVID-19 treatment or prevention.
- Participants who are receiving COVID-19 vaccines around the time of dosing of the investigational product will be asked to avoid COVID-19 vaccination within the 10 days before any vaccination in the study and within any reactogenicity period (the day of and 7 days following each intranasal vaccination).
- Inability of the study team to collect 5 mL of blood from the participant before the first vaccination (pre-vaccination blood).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04960397
| Contact: James D. Campbell | 14107065328 | jcampbel@som.umaryland.edu |
| United States, Iowa | |
| University of Iowa - Infectious Disease Clinic | Recruiting |
| Iowa City, Iowa, United States, 52242-1009 | |
| United States, Maryland | |
| University of Maryland School of Medicine - Center for Vaccine Development - Baltimore | Recruiting |
| Baltimore, Maryland, United States, 21201-1509 | |
| United States, North Carolina | |
| Duke Human Vaccine Institute - Duke Vaccine and Trials Unit | Recruiting |
| Durham, North Carolina, United States, 27704 | |
| United States, Tennessee | |
| Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center | Recruiting |
| Nashville, Tennessee, United States, 37232-2573 | |
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT04960397 |
| Other Study ID Numbers: |
20-0009 75N93019C00055 |
| First Posted: | July 13, 2021 Key Record Dates |
| Last Update Posted: | October 10, 2022 |
| Last Verified: | October 3, 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Healthy Pediatric Population Immunogenicity Influenza |
M2SR H3N2 Influenza Vaccine Phase 1b Sing2016 M2SR H3N2 Influenza Vaccine |
|
Influenza, Human Respiratory Tract Infections Infections Orthomyxoviridae Infections |
RNA Virus Infections Virus Diseases Respiratory Tract Diseases |